Wayne Shaw
Research Subjects
Wayne Shaw has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alan J Sinclair
University of Bedfordshire
1 shared publication - Albert Fung
Janssen Research & Development, LLC, 920 Route 202 South, Raritan NJ 08869, USA
1 shared publication - Bruce W. Bode
Atlanta Diabetes Associates, Atlanta, Georgia, USA
1 shared publication - Cristiana Mayer
Janssen Research and Development, LLC, Titusville, NJ
1 shared publication - Gary Meininger
Janssen Research & Development, LLC, Raritan, NJ
1 shared publication - Keith Usiskin
Janssen Research & Development, LLC, 920 Route 202 South, Raritan NJ 08869, USA
1 shared publication
Latest Publications
- Open Access
- 18 April 2014
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 14 (1) , 37
Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of patients with type 2 diabetes mellitus (T2DM). The efficacy and safety of canagliflozin were evaluated in patients with T2DM 1c and fasting plasma glucose relative to placebo in patients <65 and ≥65 years of age. Both canagliflozin doses reduced body weight and systolic BP relative to placebo in patients <65 and ≥65 years of age. Incidence of overall AEs was similar across all treatment groups in patients <65 and ≥65 years of age. Incidences of serious AEs and AE-related discontinuations were similar across all treatment groups in patients <65 years of age and higher with canagliflozin 100 mg than other groups in patients ≥65 years of age. As in patients <65 years of age, incidences of genital mycotic infections and osmotic diuresis-related AEs were higher with canagliflozin relative to placebo in those ≥65 years of age. Incidences of urinary tract infections (UTIs), renal-related AEs, AEs related to volume depletion, and documented hypoglycaemia episodes were similar across all treatment groups in patients ≥65 years of age; no notable trends were observed with canagliflozin 100 and 300 mg relative to placebo in these AEs among patients <65 years of age. Changes in lipid parameters with canagliflozin were similar in both age subsets. Canagliflozin improved glycaemic control, body weight, and systolic BP, and was generally well tolerated in older patients with T2DM. ClinicalTrials.gov, NCT01081834 ; NCT01106677 ; NCT01106625 ; NCT01106690 .
- 18 April 2014
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 14 (1) , 37
Open AccessEfficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of patients with type 2 diabetes mellitus (T2DM). The efficacy and safety of canagliflozin were evaluated in patients with T2DM 1c and fasting plasma glucose relative to placebo in patients <65 and ≥65 years of age. Both canagliflozin doses reduced body weight and systolic BP relative to placebo in patients <65 and ≥65 years of age. Incidence of overall AEs was similar across all treatment groups in patients <65 and ≥65 years of age. Incidences of serious AEs and AE-related discontinuations were similar across all treatment groups in patients <65 years of age and higher with canagliflozin 100 mg than other groups in patients ≥65 years of age. As in patients <65 years of age, incidences of genital mycotic infections and osmotic diuresis-related AEs were higher with canagliflozin relative to placebo in those ≥65 years of age. Incidences of urinary tract infections (UTIs), renal-related AEs, AEs related to volume depletion, and documented hypoglycaemia episodes were similar across all treatment groups in patients ≥65 years of age; no notable trends were observed with canagliflozin 100 and 300 mg relative to placebo in these AEs among patients <65 years of age. Changes in lipid parameters with canagliflozin were similar in both age subsets. Canagliflozin improved glycaemic control, body weight, and systolic BP, and was generally well tolerated in older patients with T2DM. ClinicalTrials.gov, NCT01081834 ; NCT01106677 ; NCT01106625 ; NCT01106690 .